Activatable clostridial toxins

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S236100, C435S069700, C514S002600, C514S012200, C530S350000

Reexamination Certificate

active

08071110

ABSTRACT:
Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.

REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7811584 (2010-10-01), Steward et al.
patent: 2003/0180289 (2003-09-01), Foster et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2008/0032930 (2008-02-01), Steward et al.
patent: 2008/0032931 (2008-02-01), Steward et al.
patent: 2008/0081355 (2008-04-01), Dolly et al.
patent: 2008/0161226 (2008-07-01), Steward et al.
patent: 2008/0161543 (2008-07-01), Steward et al.
patent: 2008/0182294 (2008-07-01), Dolly et al.
patent: WO 94/21300 (1994-09-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 99/55359 (1999-11-01), None
patent: WO 2004/024909 (2004-03-01), None
patent: WO 2005/023309 (2005-03-01), None
patent: WO 2006/027207 (2006-03-01), None
patent: WO 2006/059093 (2006-06-01), None
patent: WO 2006/059105 (2006-06-01), None
patent: WO2006/059113 (2006-06-01), None
U.S. Appl. No. 11/610,440, filed Dec. 13, 2006, Dolly et al.
U.S. Appl. No. 11/781,359, filed Jul. 23, 2007, Dolly et al.
U.S. Appl. No. 11/782,112, filed Jul. 24, 2007, Dolly et al.
U.S. Appl. No. 11/832,108, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/845,167, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/832,173, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/833,142, filed Aug. 2, 2007, Steward et al.
U.S. Appl. No. 11/833,720, filed Aug. 3, 2007, Steward et al.
U.S. Appl. No. 11/834,068, filed Aug. 6, 2007, Steward et al.
U.S. Appl. No. 11/844,780, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,850, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,885, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,929, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,919, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,899, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,517, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,546, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/845,252, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,284, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,320, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,345, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,466, filed Aug. 27, 2007, Steward et al.
Herreros et al, “C-Terminal Half of Tetanus Toxin Fragment C is Sufficient for Neuronal Binding and Interaction with a Putative Protein Receptor”, Biochemical Journal, vol. 347, No. Part 1, pp. 199-204, Apr. 1, 2001.
Rummel et al, “The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interation”, Molecular Microbiology, pp. 631-643, Dec. 15, 2003.
Halpern et al, “Characterization of the receptor-binding domain of tetanus toxin”, Journal of Biological Chemistry, pp. 11188-11192, May 25, 1993.
Borodic et al, “Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin”, Jankovic J, ed. Neurological Disease and Therapy, 25,pp. 119-157, 1994.
Brubaker et al, Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors, Receptors and Channels, 8, pp. 179-188, 2002.
Mayo et al, International Union of Pharmacology. XXXV. The Glucagon Receptor Family, Pharmacological Reviews; 55, pp. 167-194, 2003.
Rosselin, The Receptors of the VIP Family Peptides (VIP, Secretin, GRF, PHI, PHM, GIP, Glucagon and Oxyntomodulin). Specifities and Identity, Peptides, vol. 7, Suppl. 1, pp. 89-100, 1986.
Tonello et al, “Tetanus and Botulinum Neurotoxins a Novel Group of Zinc-Endopeptidases”, Intracellular Protein Catabolism, Adv. Exp. Med. & Biol. 389, pp. 251-260 (1996).
Li, Yan et al., “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain”,Biochemistry(1994), 33(22), 7014-20 CODEN: Bichaw; Issn: 0006-2960: pp. 7014-7020.
Coffield et al., “The Site and Mechanism of Action of Botulinum Neurotoxin”,Neurological Disease and Therapy, pp. 3-13, 25 (Jankovic J. & Hallett M. eds. 1994).
Foran et al, “Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine Release”, Biochem. 35: pp. 2630-2636 (1996).
Dolly et al, “Probing the process of transmitter release with botulinum and tetanus neurotoxins” Seminars in Neuroscience, 6(3): pp. 149-158 (1994).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxiicity after Reconstruction with the Heavy Chain”, Biochemistry 34: pp. 15175-15181 (1995).
Lacy et al, “Crystal structure of botulinum neurotoxin type A and implications for toxicity” Nature Struct. Biol. Oct; 5 (10): pp. 898-902 (1998).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Cahins of Tetanus Toxin and Botulinum Neurotoxin Type A”, J. Biol. Chem.: pp. 14721-14729 (1992), Hutchison et al.
“Mutagenesis at a Specific Position in a DNA Sequence”, J. Biol. Chem. 253: No. 18, Sep. 25 issue, pp. 6651-6560 (1978).
Li et al, “Expression and Characterization of the Heavy Chain of Tetanus Toxin: Reconstruction of the Fully-Recombinant Dichain Proetin in Active Form”, J. Biochem. 125: pp. 1200-1208 (1999).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Activatable clostridial toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activatable clostridial toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activatable clostridial toxins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4297859

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.